Names To Watch With XBI Hit
Insights - Biotech (XBI) is back under $125 after a small September rally. On biotech weakness, we’re looking to buy companies on our watchlist or add to … Continue Reading
PremiumSearch Results for gene therapy
This Name Is Overlooked While Rest of IL-2 Space Is In A Frenzy
Research - Medicenna (MDNA) is developing a next-gen IL-2 candidate against solid tumors. The company expects to report Phase 1 biomarker data by the end of 2021, … Continue Reading
Premium
Eloxx Setting Expectations for Phase 2 CF Data
Insights - Eloxx (ELOX) provided a Q2 business update earlier this week, and everything was on schedule. Based on enrollment at the end of June, the company remainson track to report … Continue Reading
PremiumConference: Medicenna (MDNA) CEO On Their Drug’s Best-in-Class Potential in IL-2 Space
Digital Conferences - Transcript of Digital Conference Participants Fahar Merchant – President & Chief Executive Officer, Medicenna Mann Muhsin – Chief Medical Officer, Medicenna Elizabeth Williams – Chief … Continue Reading
Read now
FDA Places Magenta’s ADC Conditioning Program On Hold
Insights - Magenta announced that the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning agent MGTA-117. As a result, MGTA will need … Continue Reading
PremiumEloxx To Present CF Data in Early Q4 2021
Insights - Yesterday, Eloxx (ELOX) was down 17% to $1.60 after the company provided an enrolment update for ELX-02 Phase 2 in cystic fibrosis. The company expects to present … Continue Reading
PremiumEloxx Risk-Reward Compelling Ahead of Cystic Fibrosis Data
Research - Eloxx (ELOX) is developing a cystic fibrosis treatment for the 12% of patients that Vertex’s therapies cannot treat. The mechanism of action in the ribosome … Continue Reading
Premium